Prism Biotech
Prelaunch prescriber profiling and targeting
Account Representative
About the job
- Demonstrated sales abilities if a college degree is not held.
- Ability to develop strategic, long-term customer relationships to help patients and achieve business results.
- Ability to communicate pharmacodynamics and clinical evidence to physicians and other clinical audiences.
- Alignment with the corporate values of putting the patient at the center, collaboration, relentless pursuit of excellence, and trust.
- Strong organizational and time-management skills.
- Familiarity with databases, statistics, product lines, and current medical issues.
- Strong business acumen and ability to understand market opportunities.
- Execute the brand and sales strategy to demonstrate product value to key customers.
- Use knowledge of local market trends, institutions, and key customers to optimize the national strategy and drive territory-level business results.
- Execute established team business and account plans to improve brand usage within key accounts.
- Collaborate with matrix team members to improve territory performance and elevate brand value.
- Use internal pharmaceutical sales resources, including market data and analysis, to shape territory business plans and drive business results and patient impact.
- Use internal systems for call planning and recording call activity.
- Identify opportunities to improve organizational efficiency and processes to positively impact business results.
- A college degree is preferred.
About the company
Prism Biotech provides field sales and medical affairs services to support pharmaceutical launches. It deploys pharmaceutical sales reps and medical science liaisons before product approval to collect prescriber information through office visits. The data gathered is combined with existing records to create a profile of key prescriber targets and disease states. This profiling happens before a launch so the sales team is prepared with identified targets and relevant physician insights. Prism Biotech differentiates itself by offering a full-service prelaunch target physician profiling workflow, aligning early market intelligence with product planning. The company’s goal is to prime and ready the sales force with accurate, ready-to-target physician profiles ahead of a brand’s approval and launch.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Upper Merion Township, Pennsylvania
Founded
2019
Get referred to Prism Biotech
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ono paid PRISM a milestone in November 2025, validating PepMetics execution.
- E7386 Phase 1 results were published in January 2026, extending clinical credibility.
- March 2026 Receptor.AI deal adds AI-driven discovery leverage for difficult targets.
What critics are saying
- August 2026 nine-month loss widened to ¥845.7 million; burn remains heavy.
- Servier terminated its collaboration in October 2025, proving partner churn hits PRISM.
- September 2026 cash burn and no guidance set up a dilutive 2027 financing crunch.
What makes Prism Biotech unique
- PepMetics targets intracellular protein-protein interactions, a hard, scarce drug-discovery niche.
- PRISM BioLab monetizes by out-licensing programs to Eisai, Ono, and Servier.
- 2026 collaborations with Receptor.AI and Talus deepen platform optionality.
Help us improve and share your feedback! Did you find this helpful?